AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Views & Reviews
May 21, 2021
Open Accessinfographic

Genetic Influences on Hippocampal Subfields
An Emerging Area of Neuroscience Research

Natalia Vilor-Tejedor, PhD https://orcid.org/0000-0003-4935-6721, Tavia E. Evans, PhD https://orcid.org/0000-0003-2390-286X, Hieab H. Adams, MD, PhD https://orcid.org/0000-0003-3687-2508, José María González-de-Echávarri, MD, MSc https://orcid.org/0000-0002-6130-9111, José Luis Molinuevo, MD, PhD https://orcid.org/0000-0003-0485-6001, Roderic Guigo, PhD https://orcid.org/0000-0002-5738-4477, Juan Domingo Gispert, PhD https://orcid.org/0000-0002-6155-0642, and Grégory Operto, PhD https://orcid.org/0000-0002-0208-1671Authors Info & Affiliations
June 2021 issue
7 (3)
https://doi.org/10.1212/NXG.0000000000000591
Letters to the Editor
Track CitationsAdd to favorites
Full Text HTML
Download PDF

Related Infographic

Letters to the Editor

Information & Authors

Information

Published In

Neurology® Genetics
Volume 7 • Number 3 • June 2021

Copyright

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Publication History

Received: August 26, 2020
Accepted: March 3, 2021
Published online: May 21, 2021
Published in print: June 2021

Permissions

Request permissions for this article.

Disclosure

N. Vilor-Tejedor, T.E. Evans, H.H. Adams, and J.M. González-de-Echávarri report no disclosures. J.L. Molinuevo has served/serves as a consultant or at advisory boards for the following for-profit companies or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. R. Guigo, J.D. Gispert, and G. Operto report no disclosures. Go to Neurology.org/NG for full disclosures.

Authors

Affiliations & Disclosures

Natalia Vilor-Tejedor, PhD https://orcid.org/0000-0003-4935-6721
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NV-T is funded by a post-doctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministerio de Ciencia, Innovación y Universidades – Spanish State Research Agency.
Research Support, Academic Entities:
1.
N V-T has been partially supported by the European Molecular Biology Organization (EMBO) Postdoctoral Fellowships
Research Support, Foundations and Societies:
1.
This research has been also supported by EU COST Action 15120 Open Multiscale Systems Medicine (OpenMultiMed) and the Alzheimer Nederland Project (WE.15-2019-09)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Tavia E. Evans, PhD https://orcid.org/0000-0003-2390-286X
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
ZonMW, 916.19.151, supported by, 2019-2021
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzhimer Nederland
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Hieab H. Adams, MD, PhD https://orcid.org/0000-0003-3687-2508
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
José María González-de-Echávarri, MD, MSc https://orcid.org/0000-0002-6130-9111
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
José Luis Molinuevo, MD, PhD https://orcid.org/0000-0003-0485-6001
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
(1) Roche Diagnostics(2) BioCross(3) GE Healthcare(4) Genentech(5) Novartis(6) Lundbeck(7) Oryzon(8) Biogen(9) Lilly(10) Janssen(11) Green Valley(12) MSD(13) Esai(14) Alector(15) ProMIS Neurosciences
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Roche Diagnostics
Editorial Boards:
1.
(1) Alzheimer's and Dementia, Associate editor (2019-...)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
H. Lundbeck A/S, VP clinical development, from Nov 2020
Consultancies:
1.
(1) Roche Diagnostics(2) BioCross(3) GE Healthcare(4) Genentech(5) Novartis(6) Lundbeck(7) Oryzon(8) Biogen(9) Lilly(10) Janssen(11) Green Valley(12) MSD(13) Esai(14) Alector(15) ProMIS Neurosciences
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) La Caixa Foundation
Research Support, Government Entities:
1.
(1) Instituto de Salud Carlos III, PI19/00117, PI, 2020-2022(2) Innovative Medicines Initiative Joint Undertaking, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution, grant agreement n° 115568, PI, 2014-2018(3) Innovative Medicines Initiative Joint Undertaking, resources of which are composed of financial contribution from the European Union?s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies? in kind contribution. Grant agreement n° 115736, PI, 2016-2020(4) Innovative Medicines Initiative 2 Joint undertaking. This Joint Undertaking receives support from the European Union?s Horizon 2020 research and innovation programme and EFPIA. Grant agreement No 115952; PI, 2018-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Roderic Guigo, PhD https://orcid.org/0000-0002-5738-4477
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Juan Domingo Gispert, PhD https://orcid.org/0000-0002-6155-0642
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Biogen, speaker fee Philips, speaker fee
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) GE Healthcare, (2) Roche Diagnostics, (3) Hoffmann La Roche
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Grégory Operto, PhD https://orcid.org/0000-0002-0208-1671
From the Barcelonaβeta Brain Research Center (BBRC) (N.V.-T., J.M.G.-d-E., J.L.M., J.D.G., G.O.), Pasqual Maragall Foundation; Centre for Genomic Regulation (CRG) (N.V.-T., R.G.), the Barcelona Institute for Science and Technology, Spain; Department of Clinical Genetics (N.V.-T., T.E.E., H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; Universitat Pompeu Fabra (N.V.-T., J.M.G.--E., J.L.M., R.G., J.D.G.), Barcelona, Spain; Department of Radiology and Nuclear Medicine (H.H.A.), Erasmus Medical Center, Rotterdam, the Netherlands; IMIM (Hospital del Mar Medical Research Institute) (J.L.M., J.D.G., G.O.), Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (J.L.M., G.O.); and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence Dr. Vilor-Tejedor [email protected]
Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Reetta-Liina Armio,
    • Heikki Laurikainen,
    • Tuula Ilonen,
    • Maija Walta,
    • Elina Sormunen,
    • Arvi Tolvanen,
    • Raimo K. R. Salokangas,
    • Nikolaos Koutsouleris,
    • Lauri Tuominen,
    • Jarmo Hietala,
    Longitudinal study on hippocampal subfields and glucose metabolism in early psychosis, Schizophrenia, 10, 1, (2024).https://doi.org/10.1038/s41537-024-00475-z
    Crossref
    • Feng Deng,
    • Maria-Eleni Dounavi,
    • Emanuele R.G. Plini,
    • Karen Ritchie,
    • Graciela Muniz-Terrera,
    • Siobhan Hutchinson,
    • Paresh Malhotra,
    • Craig W. Ritchie,
    • Brian Lawlor,
    • Lorina Naci,
    Cardiovascular risk of dementia is associated with brain–behaviour changes in cognitively healthy, middle-aged individuals, Neurobiology of Aging, 144, (78-92), (2024).https://doi.org/10.1016/j.neurobiolaging.2024.09.006
    Crossref
    • Kevin Kirchner,
    • Linda Garvert,
    • Katharina Wittfeld,
    • Sabine Ameling,
    • Robin Bülow,
    • Henriette Meyer zu Schwabedissen,
    • Matthias Nauck,
    • Henry Völzke,
    • Hans J. Grabe,
    • Sandra Van der Auwera,
    Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population, International Journal of Molecular Sciences, 24, 2, (1120), (2023).https://doi.org/10.3390/ijms24021120
    Crossref
    • Robin de Flores,
    • Solène Demeilliez-Servouin,
    • Elizabeth Kuhn,
    • Léa Chauveau,
    • Brigitte Landeau,
    • Nicolas Delcroix,
    • Julie Gonneaud,
    • Denis Vivien,
    • Gaël Chételat,
    Respective influence of beta-amyloid and APOE ε4 genotype on medial temporal lobe subregions in cognitively unimpaired older adults, Neurobiology of Disease, 181, (106127), (2023).https://doi.org/10.1016/j.nbd.2023.106127
    Crossref
    • Shahram Bahrami,
    • Kaja Nordengen,
    • Alexey A. Shadrin,
    • Oleksandr Frei,
    • Dennis van der Meer,
    • Anders M. Dale,
    • Lars T. Westlye,
    • Ole A. Andreassen,
    • Tobias Kaufmann,
    Distributed genetic architecture across the hippocampal formation implies common neuropathology across brain disorders, Nature Communications, 13, 1, (2022).https://doi.org/10.1038/s41467-022-31086-w
    Crossref
    • Zahra Taheri Zadeh,
    • Shayan Rahmani,
    • Fatemeh Alidadi,
    • Sara Joushi,
    • Khadijeh Esmaeilpour,
    Depresssion, anxiety and other cognitive consequences of social isolation: Drug and non‐drug treatments, International Journal of Clinical Practice, 75, 12, (2021).https://doi.org/10.1111/ijcp.14949
    Crossref

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text HTML

View Full Text HTML
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF